EP0782582A1 - EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5$g(a)-ANDROST-1-ENE-17$g(b)-CARBOXAMIDE - Google Patents

EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5$g(a)-ANDROST-1-ENE-17$g(b)-CARBOXAMIDE

Info

Publication number
EP0782582A1
EP0782582A1 EP96923968A EP96923968A EP0782582A1 EP 0782582 A1 EP0782582 A1 EP 0782582A1 EP 96923968 A EP96923968 A EP 96923968A EP 96923968 A EP96923968 A EP 96923968A EP 0782582 A1 EP0782582 A1 EP 0782582A1
Authority
EP
European Patent Office
Prior art keywords
epimers
formula
oxo
phenylprop
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96923968A
Other languages
German (de)
French (fr)
Inventor
Achille Panzeri
Marcella Nesi
Enrico Di Salle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Publication of EP0782582A1 publication Critical patent/EP0782582A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to two epimers of formula (I) and (ID).
  • the epimer mixture proved to be a potent inhibitor of testosterone 5 ⁇ -reductase enzyme both in vitro and in vivo (see data reported in Table (I) , page 33 of WO 94/03475) and therefore useful in those cases in which a reduction of androgenic activity is desired, for example, in treating benign prostatic hyperplasia, breast and prostate cancer and certain skin-hair alterations, for example, in treating acne, seborrhea, female hirsutism and male pattern baldness.
  • the two epimers can be obtained, for example, following the method described in WO 94/03475 and subsequent separation of the epimer mixture thereof. Said separation can be carried out, for example, by means of high pressure liquid chromatography (HPLC) .
  • HPLC high pressure liquid chromatography
  • the single epimers can be obtained, independently from each other, by reacting 3-oxo-4-aza-5 ⁇ - androst-l-ene-17 ⁇ -carboxylic acid with each single enantiomer of 1,1, l-trifluoro-2-phenylprop-2-yl amine previously resolved.
  • the single pure epimers can be advantageously obtained by: a) reacting 3-oxo-androst-4-ene-17 ⁇ -carboxylic acid, or a derivative thereof, with ( ⁇ ) -1, 1, l-trifluoro-2- phenylprop-2-yl amine; b) separating the two epimers of the so obtained (22RS) -N- (1,1,l-trifluoro-2-phenylprop-2-yl) -3-oxo-androst-4-ene- 17 ⁇ -carboxamide (e.g. by flash chromatography on silica gel) ; c
  • object of the present invention are the two epimers of formula (I) and (II) as reported above, and their use as 5 ⁇ - reductase inhibitors. These epimers are useful in those cases in which a reduction of androgenic activity is desired, for example, in the treatment and/or chemoprevention of benign prostatic hyperplasia and prostatic cancer. Moreover, these epimers can be used in the treatment of breast cancer and certain skin-hair alterations, for example, in the treatment of acne, seborrhea, female hirsutism and male pattern baldness.
  • the present invention relates to pharmaceutical compositions comprising one of the epimers of formula (I) or (II) , or a mixture thereof, wherein one of the epimers is present in a prevailing amount with respect to the other epimer, in combination with one or more pharmaceutically acceptable carriers and/or diluents.
  • compositions containing the compounds of the invention are usually prepared according to conventional methods and are administered in a suitable pharmaceutical form, such as, for example, one of those described in WO 94/03475.
  • the reaction mixture was heated to reflux for 4 h.
  • the reaction mixture was poured into a chilled saturated sodium chloride aqueous solution of (200 mL) and extracted with methylene chloride (3 x 100 mL) ; the organic extracts were washed with water, dried over sodium sulfate and the solvent was removed under reduced pressure. 2.150 g of the title compound were obtained.
  • the two epimers were separated by flash chromatography on silica gel (eluant: n-hexane/ethyl acetate 70:30) to yield 770 mg of the less retained (R f sup.) epimer and 700 mg of the most retained (R f inf.) epimer.
  • FCE 29331 was obtained from (+) - amine
  • FCE 29330 was obtained from (-) -amine.
  • Inhibition of 5 ⁇ -reductase was evaluated using the particulate fraction from homogenates of hyperplastic human prostates as the enzyme source.
  • the particulate fraction was prepared centrifuging prostate homogenates at 140,000 x g. The resulting pellet, washed several times, was resuspended in buffer and stored at -80°C. in aliquots containing « 10 mg protein/ml.
  • the assay for 5 ⁇ -reductase was done in a final volume of 0.5 ml, in 40 mM TRIS-HCI buffer pH 5.5, containing 1 mM dithiothreitol, 5 mM NADPH, 1 ⁇ M [ 14 C] testosterone, an aliquot of the enzyme preparation and various concentrations of the inhibitors. After 30 min. incubation at 37°C, the reaction was terminated by addition of 2 ml cold diethyl ether and the organic phase was separated, evaporated under N 2 and resuspended in ethyl acetate. Testosterone metabolites in this extract were separated in TLC on silica gel F 254 plates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the epimers: (22R)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide and (22S)-N-(1,1,1-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide useful as inhibitors of testosterone 5α-reductase enzyme, to a process for their preparation and to pharmaceutical compositions containing them.

Description

EPIMERS OF (22RS) -N- (1,1,1-TRIFLUORO-2-PHENYLPEOP-2-YL) -3-OXO- 4-AZA-5α-A DROST-l-ENE-17β-CARBOXAMIDE
The present invention relates to two epimers of formula (I) and (ID
namely (22R) -N- (1,1, 1-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-
5α-androst-l-ene-17β-carboxamide [compound of formula (I)] and
(22S) -N- (1,1, 1-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α- androst-l-ene-17β-carboxamide [compound of formula (II)] .
In the formulas of the present description the dashed line
( "H ) indicates a substituent in α configuration, i.e. below the plane of the ring, and the wedged line ( "^^* ) indicates a substituent in β configuration, i.e. above the plane of the ring. Metabolites and metabolic precursors of the compounds of formula (I) and (II) are within the scope of the present invention.
The mixture of the epimers of formula (I) and (II) in ratio 1:1, namely the compound (22RS) -N- (1,1,l-trifluoro-2- phenylprop-2-yl) -3-oxo-4-aza-5α-androst-l-ene-17β-carboxamide (laboratory code FCE 28260) , has already been described in our previous International Patent Application WO 94/03475 (see compound 41 at page 15 and Example 5, page 45), whereas the single epimer (22R) or (22S) has never been specifically mentioned therein. The epimer mixture proved to be a potent inhibitor of testosterone 5α-reductase enzyme both in vitro and in vivo (see data reported in Table (I) , page 33 of WO 94/03475) and therefore useful in those cases in which a reduction of androgenic activity is desired, for example, in treating benign prostatic hyperplasia, breast and prostate cancer and certain skin-hair alterations, for example, in treating acne, seborrhea, female hirsutism and male pattern baldness. We have now separated the two epimers from their epimeric mixture and evaluated their activity as inhibitors of testosterone 5α-reductase enzyme.
The two epimers can be obtained, for example, following the method described in WO 94/03475 and subsequent separation of the epimer mixture thereof. Said separation can be carried out, for example, by means of high pressure liquid chromatography (HPLC) . Alternatively, the single epimers can be obtained, independently from each other, by reacting 3-oxo-4-aza-5α- androst-l-ene-17β-carboxylic acid with each single enantiomer of 1,1, l-trifluoro-2-phenylprop-2-yl amine previously resolved. Additionally, as the corresponding epimeric amides obtained reacting 3-oxo-androst-4-ene-17β-carboxylic acid with (±) - 1, 1,l-trifluoro-2-phenylprop-2-yl amine are more easily separable than the corresponding 3-oxo-4-aza-5α-androst-l- ene-I7β-carboxamide epimers, the single pure epimers can be advantageously obtained by: a) reacting 3-oxo-androst-4-ene-17β-carboxylic acid, or a derivative thereof, with (±) -1, 1, l-trifluoro-2- phenylprop-2-yl amine; b) separating the two epimers of the so obtained (22RS) -N- (1,1,l-trifluoro-2-phenylprop-2-yl) -3-oxo-androst-4-ene- 17β-carboxamide (e.g. by flash chromatography on silica gel) ; c) converting the so obtained epimers separately into the final epimers of formulas (I) and (II) , according to known reactions.
Thiε synthetic route is reported in the following reaction Scheme I (the absolute configurations at C(22) are tentative) :
SCHEME I
(V) (VI)
Rfinf Rf sup [α]D +126° {cl, abs. EtOH) [α]D +187° (c1, abs. EtOH)
d) NaOH, H20, Dioxane / reflux / 3h e) (COCI)2, Toluene / RT / 3h f) (+)-PhCF3(CH3)CNH2 , Pyridine, CHCI3 / reflux / 5h g) Chromatographic separation h) KMn04, Nal04, tBuOH / 35-40 βC / 2h SCHEME1 (cont'd.
[α]D +46°(c1,CHCI3) [α]D +21° (c 1, CHCI3)
i) NH3> (CH2OH)2 / 0 - 180 °C / 2h
I) H2/PtO2 , AcOH / 40 - 50 psi / 45 - 50 m) (PhSeO)20, PhCI/ reflux/ 5h As reported hereinbelow, in vitro biological tests for inhibition of human prostatic testosterone 5α-reductase enzyme unexpectedly showed that one of the two epimers, tested separately, is approximately two-fold more potent than the other, while the epimeric mixture, as expected, has intermediate activity.
Therefore, object of the present invention are the two epimers of formula (I) and (II) as reported above, and their use as 5α- reductase inhibitors. These epimers are useful in those cases in which a reduction of androgenic activity is desired, for example, in the treatment and/or chemoprevention of benign prostatic hyperplasia and prostatic cancer. Moreover, these epimers can be used in the treatment of breast cancer and certain skin-hair alterations, for example, in the treatment of acne, seborrhea, female hirsutism and male pattern baldness.
Furthermore, the present invention relates to pharmaceutical compositions comprising one of the epimers of formula (I) or (II) , or a mixture thereof, wherein one of the epimers is present in a prevailing amount with respect to the other epimer, in combination with one or more pharmaceutically acceptable carriers and/or diluents.
The pharmaceutical compositions containing the compounds of the invention are usually prepared according to conventional methods and are administered in a suitable pharmaceutical form, such as, for example, one of those described in WO 94/03475.
The following examples further illustrate the invention.
Example 1
(22RS) -N- (1,1,1-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α- androst-1-ene-17β-carboxamide To a suspension of 3-oxo-4-aza-5α-androstane-17β-carboxylic acid (7 g) in chloroform (100 mL) , a solution of thionyl chloride (S0C12) (35 mL) in chloroform (15 mL) was added dropwise, under nitrogen, over 30 minutes, keeping the reaction mixture at about +3°C in an ice-water bath. The suspension was stirred at room temperature for l h, and then the volatile compounds were evaporated under vacuum. A white solid was obtained. The solid was suspended in chloroform (330 mL) and the suspension was cooled to +3°C; pyridine (1.78 mL) and then
(±) -1, 1, l-trifluoro-2-phenylprop-2-yl amine (7.1 g) were added and the reaction mixture heated to 60°C for 4 h and then stirred at room temperature overnight. The reaction mixture was poured into an ammonium chloride saturated aqueous solution (500 mL) , the organic layer was separated and the aqueous layer extracted with methylene chloride (2 x 100 mL) . The combined organic extracts were washed with water, dried over sodium sulfate and the solvent was removed under vacuum. The crude was purified by flash chromatography on silica gel (eluant: methylene chloride/acetone 70:30) to yield 7.036 g of (22RS) -N- (1, 1, 1-trifluoro-2-phenylprop-2- yl) -3-oxo-4-aza-5α-androst-l-ene-17β-carboxamide [ (epimeric ratio 50:50 by HPLC (column: Partisphere C8, 4.6 x 250 mm; eluant: acetonitrile/water 50:50; flow: 1 mL/min; detector: UV at 210 nm) ] .
Example 2
Separation of the mixture into the single epimers by preparative HPLC.
Apparatus: PrepLC/System 500 (Water Associates) Columns: 2 PrepPAK-500/SILICA Eluant: Toluene/Acetic acid/methanol 100:3:3 Flow: 150 mL/min Detector: Refractive index
As the absolute configuration of the single epimers was not established by X-ray cristallography, they were identified by laboratory code numbers FCE 29330 for the first eluted epimer (Rf sup.) and FCE 29331 for the second eluted compound (Rf inf. ) .
FCE 29330
NMR (CDC13) δ: 7.50-7.33 (m, 5H, Ph) , 6.78 (d, IH, H(l)), 5.87 (bs, IH, NH(21)), 5.82 (dd, IH, H(2)), 5.48 (bs, IH, NH(4)), 3.33 (dd, IH, H(5a)), 2.07 (s, 3H, C(CF3)CH3Ph) , 0.98 (s, 3H, Me(19)), 0.72 (s, 3H, Me(18)).
[α]D +46.7° (c 0.89, abs. EtOH)
FCE 29331
NMR (CDCI3) δ: 7.50-7.33 (m, 5H, Ph) , 6.78 (d, IH, H(l)), 5.90 (bs, IH, NH(21)) , 5.82 (dd, IH, H(2)) , 5.48 (bs, IH, NH(4)), 3.33 (dd, IH, H(5a)), 2.04 (s, 3H, C(CF3) CH3Ph) , 0.98 (s, 3H, Me (19)) , 0.68 (S, 3H, Me(18)) . [α]D +58.3° (c 0.061, abs. EtOH)
Example 3
Resolution of racemic (+) -1,1,1-trifluoro-2-phenylprop-2-yl amine into the single enantiomers
The racemic (±) -l, 1, 1-trifluoro-2-phenylprop-2-yl amine was treated with (+) -0,0' -dibenzoyl-D-tartaric acid; the diastereomeric salts were crystallized from isopropanol. After 5 crystallizations a partially resolved amine was obtained, in which the (+) -enantiomer prevailed [enantiomeric ratio: (+)/(-) = 88/12] .
Analogously, after 5 crystallizations of the diastereomeric salts of the racemic amine with (-) -0,0' -dibenzoyl-L-tartaric acid from isopropanol, an amine enriched in the (-)- enantiomer was obtained [enantiomeric ratio: (+)/(-) 12/88] .
Example 4
Reacting 3-oxo-4-aza-5α-androstane-17β-carboxylic acid with an amine enriched in the (+) -enantiomer [enantiomeric ratio (+)/(-) = 88/12], a mixture of FCE 29331 and FCE 29330 was obtained, in which the epimer ratio was FCE 29331/FCE 29330 = 88/12 (determined by HPLC) .
Reacting 3-oxo-4-aza-5α-androstane-17β-carboxylic acid with an amine enriched in the (-) -enantiomer [enantiomeric ratio
(+)/(-) = 12/88], a mixture of FCE 29331 and FCE 29330 was obtained, in which the epimer ratio was FCE 29331/FCE 29330 =
12/88 (determined by HPLC) .
Example 5
(22RS) -N- (l,l,l-trifluoro-2-phenylprop-2-yl) -3-oxo-androst-4- ene-17β-carboxamide (compound (VI))
To a suspension of 3-oxo-androst-4-ene-17β-carboxylic acid (compound (IV)) (2.00 g) in toluene (28 mL) and pyridine
(0.640 mL) , cooled to 10°C, a solution of oxalyl chloride
(0.68 mL) in toluene (4 mL) was added over 10 minutes. The cool g bath was removed and the mixture was stirred at room temperature for 1.5 h. The volatile compounds were removed under reduced pressure at a temperature below 40°C. The acyl chloride so obtained (compound (V) ) was dissolved in chloroform (100 mL) , cooled in an ice-water bath; triethylamine (0.876 mL) , and then a solution of (±)-l,l,l- tr.'sf-'.uo£.j-2-phenylprop-2-yl amine (2.375 g) in chloroform (4 mL) were added. The reaction mixture was heated to reflux for 4 h. The reaction mixture was poured into a chilled saturated sodium chloride aqueous solution of (200 mL) and extracted with methylene chloride (3 x 100 mL) ; the organic extracts were washed with water, dried over sodium sulfate and the solvent was removed under reduced pressure. 2.150 g of the title compound were obtained. The two epimers were separated by flash chromatography on silica gel (eluant: n-hexane/ethyl acetate 70:30) to yield 770 mg of the less retained (Rf sup.) epimer and 700 mg of the most retained (Rf inf.) epimer.
Following an analogous procedure, using a (+) - enantiomerically enriched amine [enantiomeric ratio (+)/(-) = 88/12) a final compound with the same epimeric ratio between the Rf inf. and Rf sup. epimers was obtained. This fact shows that the (+) -amine yields the Rf inf. epimer. Analogously, using the (-) -enriched amine a final compound enriched in the Rf sup. epimer was obtained.
Compound (Vib) (R£ sup.)
NMR (CDC13) δ: 7.50-7.30 (m, 5H, Ph) , 5.86 (bs, IH, NH(21)) , 5.75 (m, IH, H(4)) , 2.08 (s, 3H, C (CF3) CH3Ph) , 1.20 (s, 3H, Me(19)) , 0.76 (s, 3H, Me(18)) . [α]D +187° (c 1, abs. EtOH) Compound (Via) (R£ inf.)
NMR (CDCI3) δ: 7.50-7.30 (m, 5H, Pπ , 5.90 (bs,' IH, NH(21)), 5.75 (m, IH, H(4)), 2.04 (s, 3H, C(CF3) CH3Ph) , 1.20 (s, 3H, Me(19)), 0.72 (S, 3H, Me(18)) . [α]D +126° (c 1, abs. EtOH)
17β-[N- (l,l,l-trifluoro-2-phenylprop-2-yl)carbamoylJ -5-oxo-4- nor-3, 5-secoandrostan-3-oic acid (Rf inf.) (compound (Vila)
To a solution of N- (1, 1, 1-trifluoro-2-phenylprop-2-yl) -3-oxo- androst-4-ene-17β-carboxamide (Rf inf.) (compound (Via))
(1.70 g; 3.486 mmol) in tert-butanol (40 mL) and 2M aqueous sodium carbonate (2.09 mL) , a 2% potassium permanganate aqueous solution (1.8 mL) and a 0.75M sodium metaperiodate aqueous solution (30 mL) were added dropwise simultaneously, over about 5 minutes, at about 40°C, at such a rate that the colour of the reaction mixture remained always pink. After stirring at 40°C for 1 h and 15 minutes, the reaction mixture was cooled to room temperature, filtered and tert-butanol removed from the filtrate by evaporation under vacuum (40 mL of solvent were collected) . Then the solution was cooled to about 0°C, diluted with water, acidified with IN hydrochloric acid and extracted with ethyl acetate (4 x 30 mL) and with methylene chloride (2 x 30 mL) ; the collected organic extracts were washed with water (2 x 30 mL) , brine (20 mL) and anhydrified over sodium sulfate. Evaporation of the solvent yielded a solid foam, that was purified by flash chromatography (eluant: n-hexane/ethyl acetate 50:50) to yield 1.656 g of white solid compound. NMR (CDC13) δ: 7.30-7.50 (m, 5H, Ph) , 5.90 (bs, IH, NH) , 2.04 (s, 3H, C(CF3)CH3Ph) , 1.12 (s, 3H, Me(19)) , 0.71 (s, 3H, Me(18) ) . MS (FAB+) (m/z) : 508 [M+H]+, 490 [M-H20+H]+, 336 [M- •C(CF3)CH3Ph+ 2H]+, 173 PhCH3(CF3)C+
[α]D +108.2° (c 1, abs. Ethanol)
Following an analogous procedure starting from N- (1,1,1- trif luoro- 2 -phenylprop- 2-yl) -3-oxo-androst-4-ene-17β- carboxamide (Rf sυp.'i ( compound (Vib)) , the epimeric compound was obtained (compound VI lb) :
NMR (CDC13) δ: 7.30-7.50 (m, 5H, Ph) , 5.88 (bs, IH, NH) , 2.08 (s, 3H, C(CF3)CH3Ph) , 1.14 (s, 3H, Me(19)) , 0.78 (s, 3H, Me (18) ) .
[α]D +80° (c 1, abs. Ethanol)
N-(l,l,l-trifluoro-2-phenylprop-2-yl)-3-oxo-4-aza-androst-5- ene-17β-carboxamide (Rf inf.) (compound (Villa))
A suspension of I7β-[N- (1,1, 1-trifluoro-2-phenylprop-2- yl) carbamoyl] -5-oxo-4-nor-3,5-secoandrostan-3-oic acid (Rf inf.) (compound (Vila)) (1.540 g) in anhydrous ethylene glycol (35 mL) was saturated at 0°C with anhydrous gaseous ammonia: the secoacid dissolved completely. The solution so obtained was heated slowly to 180°C over 1 hour and 10 minutes and maintained at this temperature for 20 minutes. Then the temperature was allowed to reach room temperature over 0.5 hour. The yellowish solution was cooled to about 0°C under good stirring: the final compound began to precipitate. After diluting with water (30 mL) the stirring was continued for 0.5 hour at 0°C and the precipitate was filtered and washed with water. 1.36 g of a pale brownish solid were obtained, which was purified by flash chromatography on silica gel (eluant: n-hexane/ethyl acetate 50:50), yielded 1.090 g of the title compound.
NMR (CDC13) δ: 7.50-7.30 (m, 5H, Ph) , 5.88 (bs, IH, NH) , 4.81 (m, IH, H(6)), 2.06 (S, 3H, C(CF3)CH3Ph) , 1.12 (s, 3H, Me(19)), 0.71 (s, 3H, Me(18)). [α]D +48.5° (c 1, abs. Ethanol)
Following an analogous procedure starting from 17β-[N- (1,1, 1- trifluoro-2-phenylprop-2-yl)carbamoyl] -5-oxo-4-nor-3,5- secoandrostan-3-oic acid (Rf sup.) (compound (Vllb) ) the epimeric compound was obtained (compound (Vlllb) ) : NMR (CDCI3) δ: 7.50-7.30 (m, 5H, Ph) , 5.88 (bs, IH, NH) , 4.78 (m, IH, H(6)), 2.09 (s, 3H, C(CF3)CH3Ph) , 1.12 (s, 3H, Me(19)), 0.74 (s, 3H, Me(18)). [α]D -2° (c l, abs. Ethanol)
N- (1,1,1-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α- androstane-17β-carboxamide (R£ inf.) (compound (IXa))
A solution of N- (1,1, 1-trifluoro-2-phenylprop-2-yl) -3-oxo-4- aza-androst-5-ene-17β-carboxamide (Rf inf.) (compound
(Villa) ) (700 mg) in glacial acetic acid (45 mL) was hydrogenated in the presence of Pt02 (Adams' catalyst) (140 mg) under a pressure of 45 psi of hydrogen at 45°C for lh. The reaction mixture was cooled to room temperature, the catalyst waε filtered off and the solvent removed under reduced pressure. The residue was taken up with methylene chloride, washed with IN sulfuric acid, with brine, with aqueous sodium carbonate, with brine, with water, dried over sodium sulfate and the solvent was removed under vacuum. The crude solid so obtained was purified by flash chromatography on silica gel (eluant: toluene/ethyl acetate/methanol 75:20:5) to yield 420 mg of the title compound.
NMR (CDC13) δ: 7.50-7.30 (m, 5H, Ph) , 5.88 (bs, IH, NH(21)), 5.55 (bs, IH, NH(4)), 3.06 (dd, IH, H(5a)), 2.05 (s, 3H, C(CF3)CH3Ph) , 0.92 (s, 3H, Me(19)), 0.68 (s, 3H, Me(18)). [α]D +12° (c l, abs. Ethanol)
Following an analogous procedure starting from N- (1,1,1- trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5 -androst-5-ene-
17β-carboxamide (Rf sup.) (compound (Vlllb) ) the epimeric compound was obtained (compound (IXb) ) :
NMR (CDCI3) δ: 7.50-7.30 (m, 5H, Ph) , 5.88 (bs, IH, NH(21)), 5.55 (bs, IH, NH(4)), 3.06 (dd, IH, H(5a)), 2.05 (s, 3H, C(CF3)CH3Ph) , 0.92 (s, 3H, Me(19)) , 0.71 (s, 3H, Me(18)) . [α]D +62° (c l, abs. Ethanol)
N- (1,1,1-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α-androst- l-ene-17β-carboxamide (Rf inf.) (FCE 29331)
To a solution of N- (1, 1, l-trifluoro-2-phenylprop-2-yl) -3- oxo-4 aza-5α-androstane-17β-carboxamide (Rf inf.) (compound (IXa)) (106 mg) in chlorobenzene (5 mL) phenylseleninic anhydride (108.3 mg) was added. The solution was refluxed for 5 h, while water was removed by a Marcusson device. The solution was evaporated and the residue dissolved in methylene chloride, washed with aqueous sodium carbonate, saturated sodium chloride solution, water and dried over sodium sulfate. After evaporating the solvent, the crude was purified by flash chromatography (eluant: toluene/ethyl acetate/methanol 75:20:5) to yield 70 mg of the title compound .
NMR (CDCI3) δ: 7.50-7.33 (m, 5H, Ph) , 6.78 (d, IH, H(l)) , 5.90 (bs, IH, NH(21)), 5.82 (dd, IH, H(2)), 5.48 (bs, IH, NH(4)), 3.33 (dd, IH, H(5a)), 2.04 (s, 3H, C(CF3) CH3Ph) , 0.98 (s, 3H, Me(19)), 0.68 (s, 3H, Me (18)) . [α]D +46° (c 1, CHC13)
Following an analogous procedure starting from N- (1,1,1- trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α-androstane-17β- carboxamide (Rf sup.) (compound (IXb) ) the epimeric compound FCE 29330 was obtained:
NMR (CDCI3) δ: 7.50-7.33 (m, 5H, Ph) , 6.78 (d, IH, H(l)) , 5.87 (bs, IH, NH(21)) , 5.82 (dd, IH, H(2)), 5.48 (bs, IH, NH(4)) , 3.33 (dd, IH, H(5a)) , 2.07 (s, 3H, C(CF3) CH3Ph) , 0.98 (s, 3H, Me(19)) , 0.72 (s, 3H, Me(18)) . [α]D +21° (c 1, CHC13)
As shown by this example, FCE 29331 was obtained from (+) - amine, wherease FCE 29330 was obtained from (-) -amine.
IN VITRO ASSAY OF 5α-REDUCTASE INHIBITION
Inhibition of 5α-reductase was evaluated using the particulate fraction from homogenates of hyperplastic human prostates as the enzyme source. The particulate fraction was prepared centrifuging prostate homogenates at 140,000 x g. The resulting pellet, washed several times, was resuspended in buffer and stored at -80°C. in aliquots containing « 10 mg protein/ml. The assay for 5α-reductase was done in a final volume of 0.5 ml, in 40 mM TRIS-HCI buffer pH 5.5, containing 1 mM dithiothreitol, 5 mM NADPH, 1 μM [14C] testosterone, an aliquot of the enzyme preparation and various concentrations of the inhibitors. After 30 min. incubation at 37°C, the reaction was terminated by addition of 2 ml cold diethyl ether and the organic phase was separated, evaporated under N2 and resuspended in ethyl acetate. Testosterone metabolites in this extract were separated in TLC on silica gel F 254 plates
(Merck), using chloroform, acetone and n-hexane (2:1:2) as developing solvent system. Radioactivity on the plate was scanned and analyzed from quantitative plots printed by a TLC-analyzer (Berthold) . The fractional 5α-reduction of testosterone was calculated by relating the 14C-radioactivity in the 5α-reduced metabolites
(5α-dihydrotestosterone, 3α- and 3β-androstanediols) regions to the total radioactivity in the testosterone and 5α-reduced metabolites regions. The concentration of each compound required to reduce control 5α-reductase activity by 50% (IC50) was determined by plotting % inhibition versus log of inhibitor concentration. The results obtained on the single epimers FCE 29330 and FCE 29331, and on the racemic mixture FCE 28260 are reported in the following Table 1.
Table 1 In vitro inhibition of human prostatic 5α-reductase by stereoisomers of FCE 28260
Compound IC50 (nM)
FCE 28260 12
FCE 29330 17 FCE 29331 8 From the results reported in Table 1 it is evident that the epimer FCE 29331 is approximately two-fold more potent than the other epimer FCE 29330. The mixture FCE 28260, as expected, shows intermediate activity.

Claims

CIAIMS
1. Epimers of formula (I) and (II)
i.e. (22R) -N- (1,1,1-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza- 5α-androst-l-ene-I7β-carboxamide [compound of formula (I)] and (22S) -N- (1,1,1-trifluoro-2-phenylprop-2-yl) -3-oxo-4-aza-5α- androst-l-ene-17β-carboxamide [compound of formula (II)].
2. A process for preparing an epimer of formula (I) or (II) according to claim 1, which comprises separating the single epimers from the corresponding epimer mixture.
3. A process for preparing an epimer of formula (I) or (II) according to claim 1, which comprises reacting 3-oxo-4- aza-5α-androst-l-ene-17β-carboxylic acid with each single enantiomer of 1, 1,1-trifluoro-2-phenylprop-2-yl amine previously resolved.
4. A process for preparing an epimer of formula (I) or (II) according to claim 1, which comprises: a) reacting 3-oxo-androst-4-ene-17β-carboxylic acid, or a derivative thereof, with (±) -l, l, l-trifluoro-2- phenylprop-2-yl amine; b) separating the two epimers of the so obtained (22RS) -N- (1, 1, 1-trifluoro-2-phenylprop-2-yl) -3-oxo-androst-4-ene- 17β-carboxamide; c) converting the so obtained epimers separately into the final epimers of formulas (I) and (II) , according to known reactions.
5. A pharmaceutical composition comprising one of the epimers of formula (I) or (II) according to claim 1, or a mixture thereof, wherein one of the epimers is present in a prevailing amount with respect to the other epimer, in combination with one or more pharmaceutically acceptable carriers and/or diluents.
6. A compound of formula (I) or (II) as defined in claim 1, for use as inhibitor of testosterone 5α-reductase enzyme.
7. A compound of formula (I) or (II) as defined in claim 1, for use as an anti-androgenic agent.
8. A compound of formula (I) or (II) according to claim 1, for use in the treatment and/or chemoprevention of benign prostatic hyperplasia or of prostatic cancer.
9. A compound of formula (I) or (II) according to claim 1, for use in the treatment of breast cancer, acne, seborrhea, female hirsutism and/or male pattern baldness.
EP96923968A 1995-07-21 1996-06-28 EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5$g(a)-ANDROST-1-ENE-17$g(b)-CARBOXAMIDE Withdrawn EP0782582A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI951587 1995-07-21
IT95MI001587A IT1275594B1 (en) 1995-07-21 1995-07-21 EPIMERS OF (22RS) -N- (1,1,1-TRIFLUORO-2-PHENYLPROP-2-IL) -3-BONE -4-AZA-5ALFA-ANDROST-1-ENE-17BETA-CARBOSSAMIDE
PCT/EP1996/002830 WO1997004002A1 (en) 1995-07-21 1996-06-28 EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5α-ANDROST-1-ENE-17β-CARBOXAMIDE

Publications (1)

Publication Number Publication Date
EP0782582A1 true EP0782582A1 (en) 1997-07-09

Family

ID=11372032

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96923968A Withdrawn EP0782582A1 (en) 1995-07-21 1996-06-28 EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5$g(a)-ANDROST-1-ENE-17$g(b)-CARBOXAMIDE

Country Status (17)

Country Link
EP (1) EP0782582A1 (en)
JP (1) JPH10506411A (en)
KR (1) KR970706298A (en)
CN (1) CN1159195A (en)
AR (1) AR003967A1 (en)
AU (1) AU6418396A (en)
BR (1) BR9606527A (en)
CA (1) CA2199273A1 (en)
EA (1) EA199700045A1 (en)
HU (1) HUP9702465A3 (en)
IL (1) IL120343A0 (en)
IT (1) IT1275594B1 (en)
MX (1) MX9701948A (en)
NO (1) NO971196D0 (en)
PL (1) PL319351A1 (en)
WO (1) WO1997004002A1 (en)
ZA (1) ZA965678B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6137399A (en) * 1998-09-09 2000-03-27 Merck & Co., Inc. Method of determining and reducing the risk of bph-related urologic events
DE60018707T2 (en) * 1999-01-25 2006-02-09 Smithkline Beecham Corp. ANTI-ANDROGENES AND METHOD FOR THE TREATMENT OF DISEASES
CN100355772C (en) * 2005-12-28 2007-12-19 天津大学 Steroid compound with 5-alpha reductase active and preparation process thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9704002A1 *

Also Published As

Publication number Publication date
IT1275594B1 (en) 1997-08-06
BR9606527A (en) 1997-12-23
HUP9702465A3 (en) 1998-11-30
ITMI951587A0 (en) 1995-07-21
HUP9702465A2 (en) 1998-05-28
ITMI951587A1 (en) 1997-01-21
CA2199273A1 (en) 1997-02-06
KR970706298A (en) 1997-11-03
AU6418396A (en) 1997-02-18
CN1159195A (en) 1997-09-10
MX9701948A (en) 1997-06-28
AR003967A1 (en) 1998-09-30
JPH10506411A (en) 1998-06-23
IL120343A0 (en) 1997-06-10
WO1997004002A1 (en) 1997-02-06
EA199700045A1 (en) 1997-12-30
NO971196L (en) 1997-03-14
PL319351A1 (en) 1997-08-04
ZA965678B (en) 1997-01-24
NO971196D0 (en) 1997-03-14

Similar Documents

Publication Publication Date Title
US5536727A (en) 17-Ethers and thioethers of 4-aza-steroids
DE3871965T2 (en) STEROID 5 ALPHA REDUCTASE INHIBITORS.
US5418238A (en) 17β-substituted 4-aza-5α-androstan-3-one derivatives
US5527807A (en) 7β-substituted-4-aza-5α-cholestan-3-ones as 5α reductase inhibitors useful in the prevention and treatment of hyperandrogenetic disorders
EP0200859A1 (en) Steroidal 5-alpha-reductase inhibitors, processes for their preparation and pharmaceutical compositions containing them
US5359071A (en) 15-substituted 4-azasteroids
EP0799239B1 (en) Diastereomerically pure 3-oxo and 3-thioxo-4-aza-androstan derivatives and the use thereof as antiandrogens
US5595996A (en) 7-substituted 4-aza cholanic acid derivatives and their use
DE68924237T2 (en) Process for the preparation of compounds for the treatment of benign prostate hypertrophy.
EP0465141A2 (en) N-monosubstituted adamantyl/norbornanyl 17beta-carbamides of3-carboxy-androst-3,5-dienes
AU4250693A (en) 17-amino substituted 4-azasteroid 5alpha-reductase inhibitors
US5525608A (en) 17b-aryl-4-aza-steroid derivatives useful as 5-alpha-reductase inhibitors
EP0782582A1 (en) EPIMERS OF (22RS)-N-(1,1,1-TRIFLUORO-2-PHENYLPROP-2-YL)-3-OXO-4-AZA-5$g(a)-ANDROST-1-ENE-17$g(b)-CARBOXAMIDE
DE69606623T2 (en) PHENYL-SUBSTITUTED 4-AZASTEROID FLUOR DERIVATIVES
MXPA97001948A (en) Epimeros de (22rs-n- (1,1,1-trifluoro-2-fenilprop-2-il) -3-oxo-4-aza-5alfa-androst-1-en-17beta-carboxam
KR830000085B1 (en) Method for preparing 4-aza-17-substituted-5α-androstan-3-ones useful as 5α-reductase inhibitors
AU696320B2 (en) 4-aza-19-norandrostane derivatives
US5583228A (en) 17-halogeno-4-azaandrostene derivatives and process for the preparation thereof
CN102838653B (en) A kind of preparation method of 3-carbonyl-4-aza-5 alpha-androstane
HABIB IBottor t) f $|| iIos (op^ p

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE

17Q First examination report despatched

Effective date: 19980619

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19981030